Dracen Pharmaceuticals, Inc.
San Diego, CA · Founded 2016 · CIK 0001728955 · Biotech · Public
small-molecule cancer therapeutic drug DRP-104
dracenpharma.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $19M
- 3 Form D · Aug 2023
- 38 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 10
- 4 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $8,488,896 | |
| Private capital raised | Form D · SEC | $8,584,398 | |
| Private capital raised | Form D · SEC | $2,285,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1853 | TBC I LLC | — | $1.0M |
| 1854 | InCarda Therapeutics, Inc. | — | $66M |
| 1855 | Recombinetics, Inc. | — | $45M |
| 1856 | Dracen Pharmaceuticals, Inc. | — | $19M |
| 1857 | Ibex Investment Holdings II LLC | — | $1.0M |
| 1858 | Purinomia Biotech, Inc. | — | $10M |
| 1859 | Apollomics Inc. | — | $10M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Dennis BilskiExecutive Officer
- Thomas EstokDirector · Executive Officer
- Robert JacksonDirector
- Jonathan LeffDirector
- Drew Pardoll, M.D., Ph.D.Director
- Asher RubinExecutive Officer
Patents
- Lyophilized Composition Comprising (s)-isopropyl 2-((S)-2-ACETAMIDO-3-(1H-INDOL-3-YL)PROPANAMIDO)-6-DIAZO-5-OXOHEXANOATE For Intravenous Administration And The Use Thereofgranted
- Lyophilized Composition Comprising (s)-isopropyl 2-((S)-2-ACETAMIDO-3-(1H-INDOL-3-YL)PROPANAMIDO)-6-DIAZO-5-OXOHEXANOATE For Subcutaneous Administration And The Use Thereofgranted
- Method Of Preparing A Don Prodrug From L-glutamic Acidgranted
- Method Of Preparing A Don Prodrug From L-pyroglutamic Acidgranted
- Combinaton Therapy With A Don Prodrug And An Immune Checkpoint Inhibitorapplication
- Lyophilized Composition Comprising (s)-isopropyl 2-((S)-2-ACETAMIDO-3-(1H-INDOL-3-YL) PROPANAMIDO)-6-DIAZO-5- Oxohexanoate For Subcutaneous Administration And The Use Thereofapplication
- Combination Therapy With A Don Prodrug And A Tigit Inhibitorapplication
- Method Of Preparing A Don Prodrug From L-glutamic Acidapplication
- Method Of Preparing A Don Prodrug From L-pyroglutamic Acidapplication
- Combinaton Therapy With A Don Prodrug And An Immune Checkpoint Inhibitorapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.